New Three-Drug cocktail targets BRCA breast cancer
NCT ID NCT03685331
First seen Nov 21, 2025 · Last updated Jun 23, 2026 · Updated 32 times
Summary
This early-phase trial tested whether combining three drugs—olaparib, palbociclib, and fulvestrant—is safe for people with BRCA-mutated, hormone receptor-positive, HER2-negative metastatic breast cancer. Nine participants received the combination to check for side effects and see if it helps control the cancer. The goal is to find a new treatment option for this specific type of advanced breast cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
olaparib, palbociclib, and fulvestrant (three drugs combined)
What this could lead to
If this combination proves safe and effective, it could offer a new treatment option for people with BRCA-mutated, hormone-positive metastatic breast cancer.
What could go wrong
This is a very early, small Phase I/II trial with only 9 participants, so results may not apply to larger groups. The triple-drug combination may cause significant side effects or fail to control the cancer.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.